833a – Efficacy in Biologic-Failure and Nonbiologic-Failure Populations in a Phase 3 Study of Ustekinumab in Moderatesevere Ulcerative Colitis: UnifiBruce E. Sands, William J. Sandborn, Silvio Danese et al.|Gastroenterology|2019Cited by 3
Tu1739 – Efficacy and Safety of Ustekinumab Through Week 16 in Patients with Moderate to Severe Ulcerative Colitis Randomized to Ustekinumab: Results from the Unifi Induction TrialSilvio Danese, Gert A. Van Assche, Bruce E. Sands et al.|Gastroenterology|2019Cited by 2
833 – Efficacy and Safety of Ustekinumab As Maintenance Therapy in Ulcerative Colitis: Week 44 Results from UnifiBruce E. Sands, Colleen Marano, William J. Sandborn et al.|Gastroenterology|2019Cited by 1
Tu1740 – Sustained Remission in Patients with Moderate to Severe Ulcerative Colitis: Results from the Phase 3 Unifi Maintenance StudyGert A. Van Assche, Laurent Peyrin‐Biroulet, Stephan R. Targan et al.|Gastroenterology|2019Cited by 1
Tu1749 – Pharmacokinetics and Exposure-Response Relationships of Intravenously Administered Ustekinumab During Induction Treatment in Patients with Ulcerative Colitis: Results from the Unifi Induction StudyOmoniyi J. Adedokun, William J. Sandborn, Zhenhua Xu et al.|Gastroenterology|2019Cited by 1